From 'too niche' to oversubscribed — what it actually took to raise MoldCo's $8M seed

"They didn't believe in the market size. I felt like I had to justify our existence as a company." — Ariana Thacker, Founder and CEO of MoldCo, on the Funded podcast, episode 58.

The short version. In February 2025, MoldCo closed an oversubscribed $8M seed round co-led by Cantos and Collaborative Fund. The company announced the round publicly the following September. Total capital raised to date: $11M. On Funded, host Jason Ye and MoldCo founder Ariana Thacker walked through what most coverage skipped — the pre-seed that closed on Thacker's prior-fund reputation, the "too niche to fund" objection that defined the first two years of MoldCo's fundraising, and the public sentiment flip that arrived in the months before this round closed. Originally appeared on Funded | How They Raised Millions on 2025-11-25.

Watch the conversation

If the embed does not load, the episode is available on YouTube.

Listen instead:

• Apple Podcasts
• Spotify
• RSS feed (Funded podcast)

Key takeaways

1. MoldCo's seed round was oversubscribed in one of the toughest stretches in healthcare fundraising in years. Thacker began at a $5M target, closed the price round at $7M, added $1M on a SAFE at a higher post-money cap, and turned down roughly $4–$5M of overflow interest along the way.
2. Cantos (Principal Amee Kapadia) wrote the first lead check. Collaborative Fund (Andrew Montgomery) followed shortly as co-lead at an equal check size. Once the round had two named leads, the remaining allocation filled quickly.
3. The pre-seed before this round closed primarily on Thacker's personal reputation — relationships from her prior fund, Conscience VC — not on investor conviction in the company itself.
4. Investor sentiment on mold-related illness shifted publicly, on social media, in the months before this round closed. By Thacker's account on the show, the shift was not driven by new clinical data.
5. Before deciding to run MoldCo herself, Thacker spent months trying to recruit an outside CEO while still navigating her own mold illness and multiple relocations.
6. MoldCo today is a clinician-led telehealth platform for mold-related illness care. Lab testing is available in 46 states. Clinical care is offered in five states today. The company is working toward nationwide care availability by 2026.

The numbers behind the announcement

Most of the public reporting summarized the deal correctly: $8M seed, co-led by Cantos and Collaborative Fund, $11M total funding to date, treatment available for $150–$300 per month for most patients, lab testing in 46 states, and clinical care in Florida, Massachusetts, Michigan, Ohio, and Texas — with nationwide care availability planned by 2026.

What the announcement did not capture is the structure of the round. Thacker described it on the show: MoldCo set out to raise $5M, closed the price round at $7M, then layered an additional $1M on a SAFE at a higher post-money cap because demand kept arriving after the round was supposed to be closed. The company ultimately declined around $4–$5M from investors who had been given an earlier yes. None of that is in a press release. It is what an oversubscribed round actually looks like from the founder's seat.

The macro backdrop matters here. The round ran "starting last year" — late 2024 — through the U.S. election cycle, the holidays, and what Thacker characterized on the show as a stretch where "almost every healthcare company is going bankrupt and having a down round." MoldCo closed in February 2025, pre-revenue at close.

"Hundreds of rejections": the pre-seed and the conviction problem

Before MoldCo, Thacker ran Conscience VC, an early-stage firm she had built from a cold-start LP base. Building that fund taught her what an extended no looks like.

"It was hundreds of rejections. I had to build an LP network from scratch. So it was so much of my heart and soul and sweat that went into Conscience. So letting go of that was also very challenging for me, too." — Ariana Thacker on Funded (≈ 00:08:05).

The pre-seed for MoldCo eventually came together, but Thacker is candid about why: it closed "primarily from personal reputation, than anything to do with the company." Several of those early investors did not fully buy MoldCo at the time they wrote their checks. Most of them are bought in now — that is a different story. What carried that round was twenty years of relationships and the muscle of an LP fundraiser who had absorbed a lot of no's.

There is a version of this story where the rational path was to ignore mold and raise another fund. Conscience was performing. Thacker's LP network was ready. But she had lived the problem and had spent enough time in the underlying science to conclude that the gaps were not going to close on their own.

"It wasn't until I came to conviction I had to let go of the concept that I was an investor because that was like very much like an ego part of me." — Ariana Thacker on Funded (≈ 00:07:46).

The "too niche" objection — and the phase shift

The pattern Jason Ye and Thacker dug into is one a lot of founders will recognize. In a market that is not yet in the zeitgeist, the dominant investor objection is not "is your team strong?" or "are your unit economics real?" — it is "does this market exist?"

For MoldCo, the single recurring objection was TAM. Investors did not believe mold-related illness was a real category. Some did not trust the underlying clinical literature. Some did not think the standard-of-care treatment protocols could be efficacious. Many, in Thacker's telling, had not done the work to know either way.

"Now every investor is coming in saying, 'Oh my gosh, how is this such a huge market unaddressed?' It's a complete phase shift in sentiment, and that just happened over the last few months." — Ariana Thacker on Funded (≈ 00:09:13).

By Thacker's reading, there is not dramatically more data in the public domain today than there was a year ago. What changed is that other credible investors began publicly engaging with mold-related illness on social media. She used a "three tigers" framing on the show: one investor talking about a problem reads as curiosity, two reads as coincidence, three reads as a category. Most investors do not move on a thesis until they have seen three tigers.

The directionality is real. MoldCo's own press release frames the company as a response to a "widespread, overlooked health crisis," and the published context that informed the deal — including Cantos's own analysis — cites the often-quoted figure that more than half of U.S. households show signs of mold, water damage, or dampness. That figure is the rough size of the problem space MoldCo addresses; it is not a clinical or diagnostic estimate. Anyone wondering whether mold could be a factor in their own symptoms should start with a clinician-supported evaluation, not a household statistic.

How the round actually came together

The first lead came from a coffee meeting in San Francisco — not a pitch meeting. Amee Kapadia, a Principal at Cantos who Thacker had known since the Conscience days, asked the right questions, did real research before the conversation, and brought a personal connection to the category. Kapadia has written publicly about her own years of unexplained symptoms — symptoms that eased after she relocated. In her own words, Cantos co-led MoldCo because "root cause medicine doesn't have to stay locked away in boutique clinics."

"I felt vindicated, I felt seen. I felt like, 'Oh my God, like finally, someone really gets what we're doing.'" — Ariana Thacker on Funded (≈ 00:22:31).

Cantos's term sheet led directly to a fast follow from Collaborative Fund, where partner Andrew Montgomery signed on as co-lead at an equal check size. Once the round had two named leads, the social signal flipped and the remaining allocation filled — to the point where MoldCo had to start turning capital away.

Jason Ye summarized the rejection-to-leads pattern more bluntly than Thacker did:

"It always seems like you're either dying of thirst or you're drowning, which is exactly what you experience of like 'no, no, no,' until all of a sudden it's like 'we can't take all this.'" — Jason Ye, host, Funded (≈ 00:18:37).

What MoldCo looks like with $11M in the bank

MoldCo is a clinician-led digital health platform for mold-related illness care. Treatment costs $150–$300 per month for most patients — a number that matters in a category where many patients spend many thousands of dollars in out-of-pocket testing and visits before they get a coherent plan. Lab testing is currently available in 46 states. Clinical care is offered in Florida, Massachusetts, Michigan, Ohio, and Texas, with nationwide care availability planned by 2026.

The clinical team includes Dr. Ritchie Shoemaker, who first defined the biotoxin-illness framework MoldCo's care builds on, and Dr. Scott McMahon, MD — the first physician to complete Dr. Shoemaker's CIRS certification program — who serves as MoldCo's Medical Director. The care team is named on MoldCo's care page.

The bigger argument behind this round is that environmental health is a category, not a niche. Customers do not come to MoldCo for a miracle outcome. They come because something feels wrong and no one has been able to tell them what to do next. The most defensible promise MoldCo can make is time compression in a broken system: a clinician-supported first step, in days instead of months, that lowers the downside of starting.

That is what $11M is meant to fund. Not louder claims. A clearer path.

The honest first step is not signing up for a protocol. It is talking to a clinician about whether mold could be a factor in what someone is experiencing. MoldCo made that step easy on purpose — readers can start with the care page when they are ready.

Sources

• Episode (primary): Ariana Thacker – From 'Too Niche' to $8M for Mold Co from Cantos and Collab Fund | Funded Ep 58. Host: Jason Ye. Published 2025-11-25.
• Announcement (primary): MoldCo Raises $8M to Address Mold & Environmental Toxins Health Crisis. PR Newswire, 2025-09-18.
• Trade coverage: MoldCo Raises $8M to Combat the "Invisible Health Crisis" of Mold Toxicity. HIT Consultant, 2025-09-19. MoldCo Raises $8M To Make Mold Detox Part of Preventive Care. Athletech News, 2025-09-18.
• Investor first-party: Your home might be making you sick. Amee Kapadia, Cantos Ventures.

Disclaimer

This article is for general education about MoldCo and its fundraising history. It is not medical advice. Mold-related illness presents differently in different people, and decisions about testing and treatment should be made with a qualified clinician. Readers who think their environment may be contributing to how they feel should start with a clinician-supported evaluation.